Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 17/20 | 0.67 |
| ▸ | KDR | P35968 | 16/20 | 0.67 |
| ▸ | LCK | P06239 | 14/20 | 0.67 |
| ▸ | SRC | P12931 | 4/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073439 | 0.90 | KDR (0.65) | TEKKDRLCKSRCPIK3CD | |
| SCHEMBL2074495 | 0.89 | TEK (0.78) | TEKKDRLCKSRCPIK3CD | |
| SCHEMBL2074795 | 0.88 | TEK (0.61) | TEKKDRLCKSRCPIK3CD | |
| SCHEMBL2071961 | 0.85 | KDR (0.71) | TEKKDRLCKSRCPIK3CD | |
| SCHEMBL2071944 | 0.84 | KDR (0.80) | TEKKDRLCKSRCPIK3CD | |
| SCHEMBL2073703 | 0.84 | KDR (0.65) | TEKKDRLCKSRCPIK3CD | |
| SCHEMBL2075330 | 0.84 | KDR (0.62) | TEKKDRLCKSRCPIK3CD | |
| SCHEMBL2075915 | 0.83 | KDR (0.70) | TEKKDRLCKSRCPIK3CD | |
| SCHEMBL2071958 | 0.83 | TEK (0.61) | TEKKDRLCKSRCPIK3CD | |
| SCHEMBL2075176 | 0.81 | KDR (0.64) | TEKKDRLCKSRCPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | TEK 1465/4885KDR 3981/4885LCK 1/4885 |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | LCK, PPP5C, DUSP1 | TEK 199/4885KDR 140/4885LCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.